[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @PRVWatch PRV Watch PRV Watch posts on X about bio, novartis, $103m, $fbio the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1885427222615363584/interactions)  - X Week XXXXX -XX% - X Month XXXXX -XX% - X Months XXXXXX +124% ### Mentions: X [#](/creator/twitter::1885427222615363584/posts_active)  - X Month XX -XX% - X Months XX +200% ### Followers: XXX [#](/creator/twitter::1885427222615363584/followers)  - X Week XXX +3.30% - X Month XXX +19% - X Months XXX +214% ### CreatorRank: undefined [#](/creator/twitter::1885427222615363584/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [cryptocurrencies](/list/cryptocurrencies) [finance](/list/finance) [exchanges](/list/exchanges) **Social topic influence** [bio](/topic/bio), [novartis](/topic/novartis), [$103m](/topic/$103m), [$fbio](/topic/$fbio), [the rare](/topic/the-rare), [$dnli](/topic/$dnli), [vertex pharma](/topic/vertex-pharma), [$vrtx](/topic/$vrtx), [aged](/topic/aged), [events](/topic/events) **Top accounts mentioned or mentioned by** [@drmakaryfda](/creator/undefined) [@respekchemistry](/creator/undefined) [@occamstooth](/creator/undefined) [@repmccaul](/creator/undefined) [@biotechch](/creator/undefined) [@daphnezohar](/creator/undefined) [@lifescivc](/creator/undefined) [@samfazeli8](/creator/undefined) [@brianskorney](/creator/undefined) [@yaronwerber](/creator/undefined) [@ericschmidt151](/creator/undefined) [@mpreminger](/creator/undefined) [@jmaraganore](/creator/undefined) [@matteispaul](/creator/undefined) [@thedawnbell](/creator/undefined) [@colongracee](/creator/undefined) [@timopler](/creator/undefined) [@parasbiotech](/creator/undefined) [@pearlf](/creator/undefined) [@investseekers](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Vertex Pharmaceuticals Incorporated (VRTX)](/topic/vertex-pharma) [Vertex Protocol (VRTX)](/topic/$vrtx) [Bluefin (BLUE)](/topic/$blue) ### Top Social Posts Top posts by engagements in the last XX hours "Sentynl Therapeutics resubmits CUTX-101 (copper histidinate) NDA for Menkes disease after a recent CRL. They expect a PRV on approval which would belong to Cyprium Therapeutics/Fortress Biotech $FBIO. I think they will be ineligible for a PRV. Write-up below critique welcomed" [X Link](https://x.com/PRVWatch/status/1990541220817567816) 2025-11-17T22:03Z XXX followers, XXX engagements "The US House passes the Give Kids a Chance Act to reauthorize the rare pediatric disease priority review voucher program to 2029. The Bill now goes onto the Senate" [X Link](https://x.com/PRVWatch/status/1995607824924377455) 2025-12-01T21:35Z XXX followers, 1904 engagements "This is a massive screw up from $DNLI Denali Therapeutics Inc. Excerpt from 8-K: "Because Denali submitted a filing of its intent to request a PRV after the initial BLA submission based on discussions with the FDA the Company may not be eligible to receive the PRV." (1/2)" [X Link](https://x.com/PRVWatch/status/1997070744115908871) 2025-12-05T22:29Z XXX followers, XXX engagements "Vertex Pharmaceuticals $VRTX plans to file for CASGEVY (exagamglogene autotemcel) in children aged 5-11 years with severe sickle cell disease in H1 2026 redeeming their Commissioners National Priority Voucher" [X Link](https://x.com/PRVWatch/status/1997371819871920257) 2025-12-06T18:25Z XXX followers, XXX engagements "The FDA Approval That Put bluebird bio to Sleep: Two years ago today the FDAs approval of LYFGENIA for sickle cell disease set off a chain of events that ultimately led to the collapse of bluebird bio. Heres an update to my thread from earlier this year. 🧵(1/11)" [X Link](https://x.com/PRVWatch/status/1997999717582508290) 2025-12-08T12:00Z XXX followers, XXX engagements "Genetix Pharmaceuticals Inc originally founded in 1992 renamed to bluebird bio in 2010 as its more commonly known. Their first drug approved was ZYNTEGLO (betibeglogene autotemcel) a gene therapy for patients with -thalassemia who require regular blood transfusions. (2/11)" [X Link](https://x.com/PRVWatch/status/1997999721109987679) 2025-12-08T12:00Z XXX followers, XX engagements "Just a month after the FDA approval of ZYNTEGLO bluebird bio received approval for SKYSONA (elivaldogene autotemcel) to treat active cerebral adrenoleukodystrophy in children. With this approval they received their second PRV which they then sold for $102M. (5/11)" [X Link](https://x.com/PRVWatch/status/1997999727753752983) 2025-12-08T12:00Z XXX followers, XX engagements "In Apr 2023 bluebird bio submitted a BLA for LYFGENIA (lovotibeglogene autotemcel) to treat patients XX years with sickle cell disease. In anticipation of receiving their third PRV they entered into a preliminary agreement to sell the future PRV to Novartis for $103M. (6/11)" [X Link](https://x.com/PRVWatch/status/1997999730379395246) 2025-12-08T12:00Z XXX followers, XX engagements "On the 8th December 2023 (two years ago today) the FDA approved LYFGENIA however denied the request for a Rare Paediatric Disease PRV; the PRV they had already promised to sell to Novartis for the $103M they greatly needed to fund operations. (7/11)" [X Link](https://x.com/PRVWatch/status/1997999732577173771) 2025-12-08T12:00Z XXX followers, XX engagements "The PRV reconsideration was denied three times over the next year and on the brink of defaulting on their loans bluebird bio agreed in Feb 2025 to be acquired by private equity Carlyle and SK Capital for $29M. The public company once worth $10B taken private for $29M. (10/11)" [X Link](https://x.com/PRVWatch/status/1997999739183194485) 2025-12-08T12:00Z XXX followers, XX engagements "The take private acquisition closed in Jun 2025 and $BLUE was delisted from Nasdaq. In Sep 2025 the company reawakened as Genetix Biotherapeutics back to the roots of the companies founding in 1992. (11/11)" [X Link](https://x.com/PRVWatch/status/1997999741351657691) 2025-12-08T12:00Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@PRVWatch PRV Watch
PRV Watch posts on X about bio, novartis, $103m, $fbio the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXX -XX%
- X Months XXXXXX +124%
Mentions: X #
- X Month XX -XX%
- X Months XX +200%
Followers: XXX #
- X Week XXX +3.30%
- X Month XXX +19%
- X Months XXX +214%
CreatorRank: undefined #
Social Influence
Social category influence stocks cryptocurrencies finance exchanges
Social topic influence bio, novartis, $103m, $fbio, the rare, $dnli, vertex pharma, $vrtx, aged, events
Top accounts mentioned or mentioned by @drmakaryfda @respekchemistry @occamstooth @repmccaul @biotechch @daphnezohar @lifescivc @samfazeli8 @brianskorney @yaronwerber @ericschmidt151 @mpreminger @jmaraganore @matteispaul @thedawnbell @colongracee @timopler @parasbiotech @pearlf @investseekers
Top assets mentioned Novartis AG (NVS) Denali Therapeutics Inc. Common Stock (DNLI) Vertex Pharmaceuticals Incorporated (VRTX) Vertex Protocol (VRTX) Bluefin (BLUE)
Top Social Posts
Top posts by engagements in the last XX hours
"Sentynl Therapeutics resubmits CUTX-101 (copper histidinate) NDA for Menkes disease after a recent CRL. They expect a PRV on approval which would belong to Cyprium Therapeutics/Fortress Biotech $FBIO. I think they will be ineligible for a PRV. Write-up below critique welcomed"
X Link 2025-11-17T22:03Z XXX followers, XXX engagements
"The US House passes the Give Kids a Chance Act to reauthorize the rare pediatric disease priority review voucher program to 2029. The Bill now goes onto the Senate"
X Link 2025-12-01T21:35Z XXX followers, 1904 engagements
"This is a massive screw up from $DNLI Denali Therapeutics Inc. Excerpt from 8-K: "Because Denali submitted a filing of its intent to request a PRV after the initial BLA submission based on discussions with the FDA the Company may not be eligible to receive the PRV." (1/2)"
X Link 2025-12-05T22:29Z XXX followers, XXX engagements
"Vertex Pharmaceuticals $VRTX plans to file for CASGEVY (exagamglogene autotemcel) in children aged 5-11 years with severe sickle cell disease in H1 2026 redeeming their Commissioners National Priority Voucher"
X Link 2025-12-06T18:25Z XXX followers, XXX engagements
"The FDA Approval That Put bluebird bio to Sleep: Two years ago today the FDAs approval of LYFGENIA for sickle cell disease set off a chain of events that ultimately led to the collapse of bluebird bio. Heres an update to my thread from earlier this year. 🧵(1/11)"
X Link 2025-12-08T12:00Z XXX followers, XXX engagements
"Genetix Pharmaceuticals Inc originally founded in 1992 renamed to bluebird bio in 2010 as its more commonly known. Their first drug approved was ZYNTEGLO (betibeglogene autotemcel) a gene therapy for patients with -thalassemia who require regular blood transfusions. (2/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements
"Just a month after the FDA approval of ZYNTEGLO bluebird bio received approval for SKYSONA (elivaldogene autotemcel) to treat active cerebral adrenoleukodystrophy in children. With this approval they received their second PRV which they then sold for $102M. (5/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements
"In Apr 2023 bluebird bio submitted a BLA for LYFGENIA (lovotibeglogene autotemcel) to treat patients XX years with sickle cell disease. In anticipation of receiving their third PRV they entered into a preliminary agreement to sell the future PRV to Novartis for $103M. (6/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements
"On the 8th December 2023 (two years ago today) the FDA approved LYFGENIA however denied the request for a Rare Paediatric Disease PRV; the PRV they had already promised to sell to Novartis for the $103M they greatly needed to fund operations. (7/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements
"The PRV reconsideration was denied three times over the next year and on the brink of defaulting on their loans bluebird bio agreed in Feb 2025 to be acquired by private equity Carlyle and SK Capital for $29M. The public company once worth $10B taken private for $29M. (10/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements
"The take private acquisition closed in Jun 2025 and $BLUE was delisted from Nasdaq. In Sep 2025 the company reawakened as Genetix Biotherapeutics back to the roots of the companies founding in 1992. (11/11)"
X Link 2025-12-08T12:00Z XXX followers, XX engagements